Clinical-grade N-(4-[¹⁸F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans.

ABSTRACT:

Background

Molecular imaging of immune cells might be a potential tool for response prediction, treatment evaluation and patient selection in inflammatory diseases as well as oncology. Targeting interleukin-2 (IL2) receptors on activated T-cells using positron emission tomography (PET) with N-(4-[¹⁸F]fluorobenzoyl)-interleukin-2 ([¹⁸F]FB-IL2) could be such a strategy. This paper describes the challenging translation of the partly manual labeling of [¹⁸F]FB-IL2 for preclinical studies into an automated procedure following Good Manufacturing Practices (GMP), resulting in a radiopharmaceutical suitable for clinical use.

Methods

The preclinical synthesis of [¹⁸F]FB-IL2 was the starting point for translation to a clinical production met

SUBMITTER: van der Veen EL 

PROVIDER: S-EPMC6637160 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature